{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:19:44Z","timestamp":1790713184754,"version":"4.1.0"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"1129","license":[{"start":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T00:00:00Z","timestamp":1636502400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,1,1]]},"abstract":"<jats:sec>\n                  <jats:title>Objective:<\/jats:title>\n                  <jats:p>Uveal melanoma (UM) commonly metastasizes to the liver. Treatment usually consists of liver-directed therapies, such as selective internal radiation therapy (SIRT). This review aimed to assess the effectiveness and safety of SIRT for hepatic metastases from UM.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods:<\/jats:title>\n                  <jats:p>The study protocol is available at OSF (https:\/\/osf.io\/vhyct\/). EMBASE and MEDLINE were searched until July 2020, using terms related to SIRT and hepatic metastases from UM. Studies reporting outcomes of SIRT in patients with UM and at least one hepatic metastasis were included. Data on overall survival (OS), hepatic progression free survival (hPFS) or tumor response were collected. The Newcastle-Ottawa Scale (NOS) was used to assess risk of bias.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results:<\/jats:title>\n                  <jats:p>11 studies were included, reporting outcomes for 268 patients with hepatic metastases from UM. Most studies (n = 9, 81.8%) were retrospective. Disease control was achieved in 170 patients (67.5%) and the median OS from time of SIRT was 12.3 months. Median hPFS was 5.4 months. Low-grade side-effects were common but serious complications were infrequent. There were two treatment-related deaths. The median NOS score was 6 (moderate risk of bias).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion:<\/jats:title>\n                  <jats:p>SIRT appears to be a safe and effective treatment for patients with unresectable hepatic metastases from UM. The certainty of our results is unclear due to predominantly retrospective data with moderate risk of bias. Further prospective studies are required to explore the role of SIRT in UM.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Advances in knowledge:<\/jats:title>\n                  <jats:p>SIRT appears to be a safe treatment for patients with unresectable hepatic metastases from UM. Further prospective work is required.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1259\/bjr.20210200","type":"journal-article","created":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T19:49:01Z","timestamp":1636573741000},"source":"Crossref","is-referenced-by-count":17,"title":["Selective internal radiation therapy for hepatic metastases of uveal melanoma: a systematic review"],"prefix":"10.1093","volume":"95","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0243-6065","authenticated-orcid":false,"given":"Harry","family":"Alexander","sequence":"first","affiliation":[{"name":"Department of Anatomy and Medical Imaging, Faculty of Medical and Health Sciences, University of Auckland , Auckland , New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Wen","sequence":"additional","affiliation":[{"name":"Department of Surgery, Auckland District Health Board , Auckland , New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Chu","sequence":"additional","affiliation":[{"name":"Department of Surgery, Auckland District Health Board , Auckland , New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Clinical Pharmacology, Faculty of Medical and Health Sciences, University of Auckland , Auckland , New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Hadden","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Faculty of Medical and Health Sciences, University of Auckland , Auckland , New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Thomas","sequence":"additional","affiliation":[{"name":"Department of Radiology, Imperial College London , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Bartlett","sequence":"additional","affiliation":[{"name":"Department of Surgery, Auckland District Health Board , Auckland , New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,11,10]]},"reference":[{"key":"2024050310481753400_b1","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/j.ophtha.2011.01.040","article-title":"Uveal melanoma: trends in incidence, treatment, and survival","volume":"118","author":"Singh","year":"2011","journal-title":"Ophthalmology"},{"key":"2024050310481753400_b2","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/ijc.11057","article-title":"Incidence of ocular melanoma in Australia from 1990 to 1998","volume":"105","author":"Vajdic","year":"2003","journal-title":"Int J Cancer"},{"key":"2024050310481753400_b3","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/01.iio.0000195852.08453.de","article-title":"Metastatic uveal melanoma therapy: current options","volume":"46","author":"Bedikian","year":"2006","journal-title":"Int Ophthalmol Clin"},{"key":"2024050310481753400_b4","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.ctrv.2012.01.002","article-title":"Uveal melanoma","volume":"38","author":"Spagnolo","year":"2012","journal-title":"Cancer Treat Rev"},{"key":"2024050310481753400_b5","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S0002-9394(98)00039-7","article-title":"The Collaborative ocular melanoma study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma II: initial mortality findings. COMS report No. 10","volume":"125","author":"Group COMS.","year":"1998","journal-title":"Am J Ophthalmol"},{"key":"2024050310481753400_b6","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1001\/archopht.123.12.1639","article-title":"Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: collaborative ocular melanoma Study Group report No. 26","volume":"123","author":"Diener-West","year":"2005","journal-title":"Arch Ophthalmol"},{"key":"2024050310481753400_b7","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1053\/j.seminoncol.2010.03.014","article-title":"Locoregional management of hepatic metastasis from primary uveal melanoma","volume":"37","author":"Sato","year":"2010","journal-title":"Semin Oncol"},{"key":"2024050310481753400_b8","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.hpb.2019.11.002","article-title":"Systematic review of liver directed therapy for uveal melanoma hepatic metastases","volume":"22","author":"Rowcroft","year":"2020","journal-title":"HPB"},{"key":"2024050310481753400_b9","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.ejso.2016.02.019","article-title":"Radiofrequency ablation and surgical resection of liver metastases from uveal melanoma","volume":"42","author":"Mariani","year":"2016","journal-title":"European Journal of Surgical Oncology"},{"key":"2024050310481753400_b10","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1158\/0008-5472.CAN-18-3158","article-title":"Her2 CAR-T cells eradicate uveal melanoma and T-cell therapy-resistant human melanoma in IL2 transgenic NOD\/SCID IL2 receptor knockout mice","volume":"79","author":"Forsberg","year":"2019","journal-title":"Cancer Res"},{"key":"2024050310481753400_b11","doi-asserted-by":"crossref","first-page":"S223","DOI":"10.1016\/S1051-0443(07)61790-4","article-title":"Yttrium-90 microspheres: radiation therapy for unresectable liver cancer","volume":"13","author":"Salem","year":"2002","journal-title":"J Vasc Interv Radiol"},{"key":"2024050310481753400_b12","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s00432-013-1564-4","article-title":"A systematic review on the safety and efficacy of yttrium-90 radioembolization for unresectable, chemorefractory colorectal cancer liver metastases","volume":"140","author":"Saxena","year":"2014","journal-title":"J Cancer Res Clin Oncol"},{"key":"2024050310481753400_b13","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0039-6257(97)00088-X","article-title":"Radiation therapy for choroidal melanoma","volume":"42","author":"Finger","year":"1997","journal-title":"Surv Ophthalmol"},{"key":"2024050310481753400_b14","doi-asserted-by":"crossref","first-page":"350","DOI":"10.2967\/jnumed.119.230870","article-title":"First-Line selective internal radiation therapy in patients with uveal melanoma metastatic to the liver","volume":"61","author":"Ponti","year":"2020","journal-title":"J Nucl Med"},{"key":"2024050310481753400_b15","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1080\/0284186X.2018.1465587","article-title":"Selective internal radiation therapy (SIRT) as treatment for hepatic metastases of uveal melanoma: a Finnish nation-wide retrospective experience","volume":"57","author":"Tulokas","year":"2018","journal-title":"Acta Oncol"},{"key":"2024050310481753400_b16","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1007\/s00270-012-0373-5","article-title":"Radioembolization as locoregional therapy of hepatic metastases in uveal melanoma patients","volume":"36","author":"Klingenstein","year":"2013","journal-title":"Cardiovasc Intervent Radiol"},{"key":"2024050310481753400_b17","doi-asserted-by":"crossref","first-page":"468","DOI":"10.2214\/AJR.10.4881","article-title":"Radioembolization as salvage therapy for hepatic metastasis of uveal melanoma: a single-institution experience","volume":"196","author":"Gonsalves","year":"2011","journal-title":"AJR Am J Roentgenol"},{"key":"2024050310481753400_b18","doi-asserted-by":"crossref","DOI":"10.1097\/COC.0000000000000033","article-title":"Yttrium-90 microsphere brachytherapy for liver metastases from uveal melanoma: clinical outcomes and the predictive value of fluorodeoxyglucose positron emission tomography","volume":"39","author":"Eldredge-Hindy","year":"2016","journal-title":"Am J Clin Oncol"},{"key":"2024050310481753400_b19","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ejrad.2017.05.005","article-title":"A systematic review of yttrium-90 radioembolization for unresectable liver metastases of melanoma","volume":"92","author":"Jia","year":"2017","journal-title":"Eur J Radiol"},{"key":"2024050310481753400_b20","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1148\/radiol.2019190199","article-title":"A prospective phase II trial of radioembolization for treatment of uveal melanoma hepatic metastasis","volume":"293","author":"Gonsalves","year":"2019","journal-title":"Radiology"},{"key":"2024050310481753400_b21","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jclinepi.2009.06.006","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"62","author":"Liberati","year":"2009","journal-title":"J Clin Epidemiol"},{"key":"2024050310481753400_b22","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"2024050310481753400_b23","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S1053-4296(03)00031-6","article-title":"CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment","volume":"13","author":"Trotti","year":"2003","journal-title":"Semin Radiat Oncol"},{"key":"2024050310481753400_b24","volume-title":"The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses","author":"Wells","year":"2000"},{"key":"2024050310481753400_b25","article-title":"A pilot study of intrahepatic yttrium-90 microsphere radioembolization in combination with intravenous cisplatin for uveal melanoma liver-only metastases","volume":"2","author":"Arulananda","year":"2019","journal-title":"Cancer Rep"},{"key":"2024050310481753400_b26","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1080\/07357900802620893","article-title":"A first report of radioembolization for hepatic metastases from ocular melanoma","volume":"27","author":"Kennedy","year":"2009","journal-title":"Cancer Invest"},{"key":"2024050310481753400_b27","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s00270-019-02366-8","article-title":"Predictors of overall and progression-free survival in patients with ocular melanoma metastatic to the liver undergoing Y90 radioembolization","volume":"43","author":"Levey","year":"2020","journal-title":"Cardiovasc Intervent Radiol"},{"key":"2024050310481753400_b28","doi-asserted-by":"crossref","first-page":"204798161557041","DOI":"10.1177\/2047981615570417","article-title":"A single-center experience in radioembolization as salvage therapy of hepatic metastases of uveal melanoma","volume":"4","author":"Schelhorn","year":"2015","journal-title":"Acta Radiol Open"},{"key":"2024050310481753400_b29","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1016\/j.jvir.2018.04.030","article-title":"Combined Effects of Yttrium-90 Transarterial Radioembolization around Immunotherapy for Hepatic Metastases from Uveal Melanoma: A Preliminary Retrospective Case Series","volume":"29","author":"Zheng","year":"2018","journal-title":"J Vasc Interv Radiol"},{"key":"2024050310481753400_b30","doi-asserted-by":"crossref","first-page":"052","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (mRECIST) assessment for hepatocellular carcinoma","volume":"30","author":"Lencioni","year":"2010","journal-title":"Semin Liver Dis"},{"key":"2024050310481753400_b31","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1007\/s00270-017-1703-4","article-title":"Cirse quality assurance document and standards for classification of complications: the cirse classification system","volume":"40","author":"Filippiadis","year":"2017","journal-title":"Cardiovasc Intervent Radiol"},{"key":"2024050310481753400_b32","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/COC.0000000000000109","article-title":"Selective internal yttrium-90 radioembolization therapy (90Y-SIRT) versus best supportive care in patients with unresectable metastatic melanoma to the liver refractory to systemic therapy: safety and efficacy cohort study","volume":"40","author":"Xing","year":"2017","journal-title":"Am J Clin Oncol"},{"key":"2024050310481753400_b33","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.jvir.2012.04.010","article-title":"Prognostic value of 18F-fluorodeoxyglucose positron emission tomography-computed tomography in predicting survival in patients with unresectable metastatic melanoma to the liver undergoing yttrium-90 radioembolization","volume":"23","author":"Piduru","year":"2012","journal-title":"J Vasc Interv Radiol"},{"key":"2024050310481753400_b34","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/CMR.0000000000000051","article-title":"Hepatic yttrium-90 radioembolization for metastatic melanoma: a single-center experience","volume":"24","author":"Memon","year":"2014","journal-title":"Melanoma Res"},{"key":"2024050310481753400_b35","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1159\/000505487","article-title":"Systemic antitumor effects and Abscopal responses in melanoma patients receiving radiation therapy","volume":"98","author":"D'Andrea","year":"2020","journal-title":"Oncology"},{"key":"2024050310481753400_b36","doi-asserted-by":"crossref","first-page":"797","DOI":"10.3111\/13696998.2015.1047779","article-title":"Cost-Effectiveness of selective internal radiation therapy using yttrium-90 resin microspheres in treating patients with inoperable colorectal liver metastases in the UK","volume":"18","author":"Pennington","year":"2015","journal-title":"J Med Econ"}],"container-title":["The British Journal of Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjr\/article-pdf\/95\/1129\/20210200\/57371079\/bjr.20210200.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjr\/article-pdf\/95\/1129\/20210200\/57371079\/bjr.20210200.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T10:50:06Z","timestamp":1714733406000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjr\/article\/doi\/10.1259\/bjr.20210200\/7451414"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,10]]},"references-count":36,"journal-issue":{"issue":"1129","published-online":{"date-parts":[[2021,11,10]]},"published-print":{"date-parts":[[2022,1,1]]}},"URL":"https:\/\/doi.org\/10.1259\/bjr.20210200","relation":{},"ISSN":["0007-1285","1748-880X"],"issn-type":[{"value":"0007-1285","type":"print"},{"value":"1748-880X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,1,1]]},"published":{"date-parts":[[2021,11,10]]},"article-number":"20210200"}}